LW-1017 / Lysoway Therapeutics - LARVOL DELTA

THE TRPML1 AGONIST, LW-1017, DOSE-DEPENDENTLY AMELIORATES DISEASE PATHOLOGY AND IMPROVES BEHAVIOR IN MOUSE MODELS OF ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE. (ADPD 2026) - "The TRPML1 agonist, LW-1017, potently and dose-dependently protected hippocampal neurons from Abeta accumulation, pTau spread, microgliosis, astrogliosis and neurodegeneration, leading to an improvement in cognitive performance. Similarly, LW-1017, dose-dependently protected nigrostriatal neurons from synuclein accumulation and propagation, preserved neuronal number, normalized neurotransmitter levels and restored normal motor performance."

Preclinical • Alzheimer's Disease • CNS Disorders • Movement Disorders • Parkinson's Disease

Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson’s Disease (Businesswire) - "Lysoway Therapeutics, Inc...announced that it has received a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). Support comes from MJFF’s Parkinson’s Disease Therapeutics Pipeline Program, which focuses on candidates with strong potential to slow or halt disease progression or alleviate burdensome symptoms for those living with Parkinson’s disease. Lysoway Therapeutics funding of $2.93 million will support the preclinical and translational development of Lysoway’s novel, highly brain-penetrant small molecule TRPML1 agonist."

Financing • Parkinson's Disease